TScan Therapeutics’ (TCRX) “Buy” Rating Reiterated at HC Wainwright

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Wednesday,Benzinga reports.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday, July 17th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen downgraded TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $5.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $6.00.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $0.76. The company’s stock had a trading volume of 177,699 shares, compared to its average volume of 703,929. TScan Therapeutics has a one year low of $0.72 and a one year high of $2.57. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.02. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. The stock has a market cap of $49.47 million, a P/E ratio of -0.79 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. As a group, analysts expect that TScan Therapeutics will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of TScan Therapeutics during the second quarter valued at $975,000. GSA Capital Partners LLP acquired a new stake in TScan Therapeutics in the second quarter worth about $537,000. Renaissance Technologies LLC lifted its holdings in TScan Therapeutics by 37.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after purchasing an additional 311,150 shares during the period. Jane Street Group LLC grew its position in TScan Therapeutics by 377.5% in the 4th quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after buying an additional 306,968 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in TScan Therapeutics by 627.5% during the 4th quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after buying an additional 292,610 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.